AgilentTechnologies said after the close of the market on Monday that revenues for itsfiscal fourth quarter were $1.04 billion, essentially flat compared to Q4 FY2014 and matching the consensus Wall Street estimate.

Its LifeSciences and Applied Markets segment recorded $515 million in revenues in thequarter, down 4 percent from $539 million a year ago. Its Diagnostics andGenomics revenues were up 4 percent to $178 million from $172 million in Q4 FY2014. Revenues from the company’s CrossLab group were up 3 percent to $342million from $332 million in the year-ago period.

Agilent'sprofit for Q4 FY 2015 rose to $140 million, or $.42 per share, from $23million, or $.07 per share, a year ago. On an adjusted basis, its EPS was $.50,beating the consensus Wall Street estimate of $.47.

Agilenthad intangible amortization of $37 million, transformation costs of $15million, acquisition and integration costs of $7 million, asset impairments of$3 million, and a tax benefit of $39 million. The company had R&D costs of$82 million in the quarter, down 15 percent from $97 million a year ago. ItsSG&A spending fell 5 percent to $297 million from $312 million.

Thecompany noted in a statement that its Life Sciences and Applied Markets Groupsaw a strong quarter for pharma offset by weakness in the industrial andacademic and government markets. The company’s Diagnostics and Genomics Groupand CrossLab Group both saw solid growth broadly.

On aconference call following the release of the results, Patrick Kaltenback,president of Agilent’s Life Sciences and Applied Markets Group, noted that thestrength in pharma was reflected in solid sales of liquid chromatographyinstrumentation, including several large deals during the quarter with big USand European drugmakers.

Kaltenbackalso cited the biopharma space as a significant growth driver, adding that thecompany had targeted this market with certain of its LC and mass specinstruments.

Agilentalso saw strong growth in its companion diagnostics business, said JacobThaysen, president of the company’s Diagnostics and Genomics Group. During thequarter Agilent received US Food and Drug Administration approval for two newcompanion diagnostics: one, a test for determining if patients with advancednon-small-cell lung cancer are likely responders to Merck’s PD-1 inhibitorKeytruda (pembrolizumab); and a second developed with Bristol-Myers Squibb fordetermining PD-L1 expression levels on the surface of NSCLC tumor cells toprovide information on the survival benefit of treatment with BMS’s Opdivo(nivolumab).

Forfull-year Fiscal 2015, Agilent said that revenues were nearly flat at $4.04billion compared to $4.05 billion in FY 2014 and matched the average analystestimate.

Thefirm's net income for the year fell to $398 million, or $1.19 per share,compared to $504 million, or $1.49 per share, in FY 2014. Adjusted EPS was$1.74, beating the consensus Wall Street estimate of $1.70.

Agilent’sR&D spending fell 8 percent during the year to $330 million from $358million in FY 2014. Its SG&A spending was down 1 percent to $1.19 billionfrom $1.20 billion a year ago.

Thecompany gave Q1 FY 2016 revenue guidance of $1.0 billion to $1.02 billion, and non-GAAPearnings guidance of $.42 to $.44 per share. For the full fiscal year 2016, itgave guidance of $4.15 billion to $4.17 billion in revenue and non-GAAPearnings of $1.85 to $1.91 per share.

Presidentand CEO Mike McMullen said the guidance assumed low single-digit growth ingovernment and academic sales and high single-digit growth in the pharma anddiagnostic and clinical markets.

InTuesday morning trading on the New York Stock Exchange, Agilent shares were up2 percent at $37.98.